Setterwalls has assisted KKR in connection with the acquisition of Immedica Pharma

Funds managed by KKR have agreed to acquire Immedica Pharma. The existing owner, the Nordic investment company Impilo, will reinvest and enter into a strategic partnership with KKR. The transaction is subject to customary conditions.

Immedica was founded in 2018 by Impilo and an experienced management team with a strong track record of launching and commercializing drugs for rare diseases in Europe. The company has built up a portfolio and pipeline of drugs, primarily within hematology/oncology as well as genetic and metabolic diseases for rare conditions with a high medical need. Immedica has rapidly expanded to become a prominent player in the field of rare diseases in Europe, with revenues of EUR 100 million and an annual growth of more than 50%.

The investment is made through KKR Health Care Strategic Growth Fund II, which focuses on investments in fast-growing healthcare companies. KKR has a long history of supporting healthcare companies globally and has invested approximately 20 billion dollars in the sector since 2004.

Bank of America Securities acted as financial advisor. Gibson Dunn, Setterwalls and Cooley acted as legal advisors. Alvarez & Marsal and PwC acted as financial and tax advisors, and Clearview Healthcare Partners assisted as commercial advisor.